ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0324

Comparative Responsiveness of Outcome Measures in Psoriatic Arthritis: Preparation for Pragmatic Trials

Courtney Stull1, Soumya Reddy2, M. Elaine Husni3, Jose Scher4, Ethan Craig1, Jessica Walsh5 and Alexis Ogdie1, 1University of Pennsylvania, Philadelphia, PA, 2NYU School of Medicine, New York, NY, 3Cleveland Clinic, Cleveland, OH, 4NYU School of Medicine, New York City, 5University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT

Meeting: ACR Convergence 2020

Keywords: Outcome measures, Patient reported outcomes, Psoriatic arthritis, Psychometrics

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous condition; this presents a challenge in how to best measure disease activity for all patients. While several outcome measures have been studied for use in traditional randomized clinical trials (RCT) of PsA, this has been done in the context of pre-defined inclusion criteria derived from a relatively homogenous population with a polyarticular phenotype and higher disease activity than is typically encountered in “real world” practice. There remains a need to determine the ideal outcomes for PsA pragmatic trials that enroll patients representative of those seen in routine care in the clinics. We aimed to investigate the responsiveness of outcome measures among patients with PsA initiating therapy in clinical practice.

Methods: Patients were enrolled in the Psoriatic Arthritis Research Consortium (PARC), a multi-center longitudinal observational cohort study, between 2017-2020. We collected data at initiation of a new treatment for PsA, including a switch in treatment, and follow-up at approximately 16 weeks. At both visits, patients completed patient-reported outcome assessments (PROs) and rheumatologists completed a comprehensive musculoskeletal exam. Change in scores were calculated for the following measures between both timepoints: Routine Assessment of Patient Index Data (RAPID3), clinical Disease Activity of Psoriatic Arthritis (cDAPSA), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), PsA Impact of Disease (PSAID), Multi-Dimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire (HAQDI), Patient Reported Outcome Measure Information System (PROMIS) physical health (PH) subscore, PROMIS mental health (MH) subscore, PROMIS fatigue, PROMIS depression, patient pain assessment, patient global assessment, physician global assessments of joints and overall, and tender (68) and swollen (66) joint counts. Standardized response means (SRMs) were calculated as the mean change between two visits divided by the standard deviation. Responsiveness cutoffs are debatable, but SRMs may roughly be considered large at >0.8, moderate 0.5-0.8, and small < 0.5.

Results: Among 177 unique patients, 266 therapy courses met inclusion criteria. The mean age was 51 years, 53% were female, mean BMI was 29.9, and 16% had axial disease. Among the 266 visits, 145 initiated a TNFi, 55 an IL17i, 96 an OSM, and 14 started another biologic or JAKi. Mean swollen and tender joint counts (66/68) at therapy initiation were 2.9 and 5.8. Responsiveness for all measures was small to moderate (Figure 1.) BASDAI was the most responsive, and tender joint count the least responsive; SRMs were similar among those initiating a biologic therapy vs. any therapy.

Conclusion: Patients with PsA switching or starting therapy in this patient population had different clinical characteristics compared to those usually enrolling in a RCT. Similarly, responsiveness of outcome measures in clinical practice looks different than traditional PsA clinical trials, with SRMs that are generally lower. This data will be useful for selecting outcome measures and calculating sample size for pragmatic trials in PsA.

Table 1. Baseline and change scores

Figure 1. Standardized Response Means of Instruments Tested. ***=Outcome measures frequently used in randomized controlled trials (RCTs) for PsA **= Outcome measures sometimes used in RCTs for PsA *= Outcome measures rarely used in RCTs for PsA Abbreviations: HAQDI=Health Assessment Questionnaire Disability Index; MD global= physician’s global assessment; SJC=swollen joint count; TJC=tender joint count; BASDAI=Bath Ankylosing Spondylitis Disease Activity Index; PSAID=PsA Impact of Disease; ; cDAPSA=clinical Disease Activity of PsA; MDHAQ=Multidimensional Health Assessment Questionnaire; PROMIS MH= PROMIS Mental Health; PROMIS PH= PROMIS Physical Health; RAPID3= Routine Assessment of Patient Index Data


Disclosure: C. Stull, None; S. Reddy, Amgen, 5, Novartis, 5, Janssen, 5, Pfizer, 5; M. Husni, Abbvie, 5, BMS, 5, Janssen, 5, Pfizer, 5, Regeneron, 5, Novartis, 5, Lilly, 5, Pfizer, 2, PASE questionnaire, 7, National Psoriasis Foundation, 6; J. Scher, UCB, 5, Janssen, 5, Abbvie, 5, Pfizer, 5, Novartis, 5, Sanofi, 5; E. Craig, None; J. Walsh, Pfizer, 2, AbbVie, 2, 5, Eli Lilly, 5, UCB, 5, Janssen, 5, Novartis, 5, Amgen, 5; A. Ogdie, abbvie, 1, amgen, 1, bms, 1, celgene, 1, corona, 1, lilly, 1, janssen, 1, novartis, 1, 2, novartis, 1, pfizer, 1.

To cite this abstract in AMA style:

Stull C, Reddy S, Husni M, Scher J, Craig E, Walsh J, Ogdie A. Comparative Responsiveness of Outcome Measures in Psoriatic Arthritis: Preparation for Pragmatic Trials [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/comparative-responsiveness-of-outcome-measures-in-psoriatic-arthritis-preparation-for-pragmatic-trials/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-responsiveness-of-outcome-measures-in-psoriatic-arthritis-preparation-for-pragmatic-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology